These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 8869475

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M, Sawamoto Y, Kamisue M, Shibata Y, Tuzi S, Kuwabara M, Tanaka I, Tanizawa T, Tanaka A, Ueda M, Kakishita E, Yoshioka A.
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP.
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [Abstract] [Full Text] [Related]

  • 25. Animal models to explore mechanisms of tolerance induction to FVIII: SCID mice and SCID-FVIII-KO mice.
    Gilles JG, Vanzieleghem B, Saint-Remy JM.
    Haematologica; 2000 Oct; 85(10 Suppl):103-6; discussion 106-7. PubMed ID: 11187860
    [No Abstract] [Full Text] [Related]

  • 26. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J.
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U.
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract] [Full Text] [Related]

  • 32. Immunological and laboratory aspects of immune tolerance.
    Kazatchkine M, Hoyer L.
    Vox Sang; 1996 Aug; 70 Suppl 1():52-9. PubMed ID: 8869470
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor.
    Aleem A, Saidu A, Abdulkarim H, Al-Diab AR, Al-Sagheer A, Qayum A, Al-Momen AK.
    Haemophilia; 2009 Jan; 15(1):210-6. PubMed ID: 19149851
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.